Zevra Therapeutics, Inc. ZVRA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $122.29M+14.9% | $106.47M+26.2% | $84.39M+36.1% | $62.02M+52.8% | $40.59M+71.9% | ||
| $17.03M+3.3% | $16.48M+0.9% | $16.33M-6.1% | $17.39M+103% | $8.59M+15.8% | ||
| $105.26M+17.0% | $89.99M+32.2% | $68.06M+52.5% | $44.63M+39.5% | $32M+97.6% | ||
| 86.1%+1.6pp | 84.5%+3.9pp | 80.7%+8.7pp | 72%-6.9pp | 78.8%+10.3pp | ||
| $13.88M+8.9% | $12.74M-31.0% | $18.48M-28.9% | $25.99M-21.4% | $33.08M-21.4% | ||
| $78.85M+1.6% | $77.62M+5.8% | $73.39M+1.0% | $72.66M+12.7% | $64.48M+17.5% | ||
| $2.56M-33.6% | $3.86M-25.2% | $5.16M-19.2% | $6.39M+1.1% | $6.32M+1.4% | ||
| $92.73M+2.6% | $90.36M-1.6% | $91.86M-6.9% | $98.65M+1.1% | $97.56M+0.6% | ||
| —— | —— | -$87.67M+26.4% | -$119.12M-65.7% | -$71.88M+17.4% | ||
| $7.72M-3.2% | $7.98M-3.0% | $8.22M-3.1% | $8.48M-1.2% | $8.59M+16.8% | ||
| $138.83M-7.2% | $149.62M+5.9% | $141.32M+0.6% | $140.52M+4,131% | -$3.49M-11.1% | ||
| —— | —— | —— | —— | —— | ||
| $191.64M+29.2% | $148.33M0.0% | $148.33M0.0% | $148.33M— | $0— | ||
| $133.4M+53.9% | $86.68M+61.6% | $53.64M+151% | $21.4M+128% | -$75.37M+16.4% | ||
| $9.18M+166% | $3.45M-81.2% | $18.32M-2.3% | $18.75M+12.8% | $16.62M+8.1% | ||
| $124.22M+49.2% | $83.23M+136% | $35.33M+1,236% | $2.64M+103% | -$91.99M+12.8% | ||
| 101.6%+23.4pp | 78.2%+36.3pp | 41.9%+37.6pp | 4.3%+231pp | -226.6%+220pp | ||
| $1.99+49.6% | $1.33+196% | $0.45+296% | -$0.23+88.0% | -$1.92+15.8% | ||
| $2.05+49.6% | $1.37+185% | $0.48+340% | -$0.20+89.6% | -$1.92+15.0% | ||
| 229.8M+2.7% | 223.6M+5.2% | 212.6M+4.0% | 204.5M+7.6% | 190.1M— | ||
| 224.4M+2.0% | 220.1M+4.3% | 211.1M+4.0% | 202.9M+6.8% | 190.1M+6.9% | ||
| $2.56M-33.6% | $3.86M-25.2% | $5.16M-19.2% | $6.39M+1.1% | $6.32M+1.4% | ||
| $1.73M+179% | -$2.18M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $9.99M+43.9% | $6.95M+32.7% | $5.23M+31.8% | $3.97M+113% | $1.86M-17.2% | ||
| $13.88M+8.9% | $12.74M-31.0% | $18.48M-28.9% | $25.99M-21.4% | $33.08M-21.4% | ||
| —— | —— | —— | —— | —— | ||
| -$136K+99.8% | -$57.64M+34.3% | -$87.67M+26.4% | -$119.12M-65.7% | -$71.88M+17.4% | ||
| $2.64M+105% | -$53.59M+34.9% | -$82.33M+26.9% | -$112.56M-72.1% | -$65.4M+18.9% | ||
| $2.64M+105% | -$53.59M+34.9% | -$82.33M+26.9% | -$112.56M-72.1% | -$65.4M+18.9% | ||
| 2.2%+52.5pp | -50.3%+47.2pp | -97.6%+83.9pp | -181.5%-20.3pp | -161.1%+180pp | ||
| -$136K+99.8% | -$57.64M+34.3% | -$87.67M+26.4% | -$119.12M-65.7% | -$71.88M+17.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $122.3M in revenue over the trailing twelve months, up 201.3% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $124.2M in net income over the trailing twelve months, a 101.6% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 86.1% and operating margin is -103.9%, with a 101.6% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $1.99.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
